



OPEN

## Near infrared-emitting multimodal nanosystem for in vitro magnetic hyperthermia of hepatocellular carcinoma and dual imaging of in vivo liver fibrosis

Shaiju S. Nazeer<sup>1,2,5</sup>, Ariya Saraswathy<sup>2,3,5</sup>, Nirmala Nimi<sup>2</sup>, Hema Santhakumar<sup>2</sup>, Parvathy Radhakrishnapillai Suma<sup>2</sup>, Sachin J. Shenoy<sup>4</sup> & Ramapurath S. Jayasree<sup>2✉</sup>

Prolonged usage of traditional nanomaterials in the biological field has posed several short- and long-term toxicity issues. Over the past few years, smart nanomaterials (SNs) with controlled physical, chemical, and biological features have been synthesized in an effort to allay these challenges. The current study seeks to develop theranostic SNs based on iron oxide to enable simultaneous magnetic hyperthermia and magnetic resonance imaging (MRI), for chronic liver damage like liver fibrosis which is a major risk factor for hepatocellular carcinoma. To accomplish this, superparamagnetic iron oxide nanoparticles (SPIONs) were prepared, coated with a biocompatible and naturally occurring polysaccharide, alginate. The resultant material, ASPIONs were evaluated in terms of physicochemical, magnetic and biological properties. A hydrodynamic diameter of 40 nm and a transverse proton relaxation rate of  $117.84 \text{ mM}^{-1} \text{ s}^{-1}$  pronounces the use of ASPIONs as an efficient MRI contrast agent. In the presence of alternating current of 300 A, ASPIONs could elevate the temperature to 45 °C or more, with the possibility of hyperthermia based therapeutic approach. Magnetic therapeutic and imaging potential of ASPIONs were further evaluated respectively in vitro and in vivo in HepG2 carcinoma cells and animal models of liver fibrosis, respectively. Finally, to introduce dual imaging capability along with magnetic properties, ASPIONs were conjugated with near infrared (NIR) dye Atto 700 and evaluated its optical imaging efficiency in animal model of liver fibrosis. Histological analysis further confirmed the liver targeting efficacy of the developed SNs for Magnetic theranostics and optical imaging as well as proved its short-term safety, in vivo.

In the last two decades, advances in nanomedicine have vastly improved the diagnosis and therapy of various diseases. However, repeated exposure to these nanomaterials raises more challenges of systemic toxicity, biocompatibility, less photostability and non-targeted distribution inside the body. Smart nanomaterials are superior to traditional nanosystems because they have regulated physical, chemical, and biological properties. Based on the stimulus required to trigger the response, SNs can be classified into physical, thermal, electrical/electrochemical, optical, magnetic, pH/redox/enzyme responsive nanomaterials<sup>1,2</sup>. Due to their unique characteristics, SNs are excellent choice for several applications, including biosensors, controlled drug release, and the treatment of numerous diseases. Smart nanomaterials employed in cancer diagnostics and imaging respond only to the tumour microenvironment where they 'turn on', while they remain inert in normal cells, reducing the side-effects<sup>1-4</sup>.

<sup>1</sup>Department of Chemistry, Indian Institute of Space Sciences and Technology, Thiruvananthapuram 695547, Kerala, India. <sup>2</sup>Division of Biophotonics and Imaging, Biomedical Technology Wing, Sree Chitra Tirunal Institute for Medical Sciences & Technology, Poojappura, Thiruvananthapuram 695 012, Kerala, India. <sup>3</sup>Department of Physics, HHMSPBNSS College, Thiruvananthapuram 695 040, Kerala, India. <sup>4</sup>Division of In Vivo Models and Testing, Biomedical Technology Wing, Sree Chitra Tirunal Institute for Medical Sciences & Technology, Poojappura, Thiruvananthapuram 695 012, Kerala, India. <sup>5</sup>These authors contributed equally: Shaiju S. Nazeer and Ariya Saraswathy. ✉email: jayasree@sctimst.ac.in; jayashreemenon@gmail.com

Among smart nanomaterials, magneto-responsive smart nanomaterials (MRSNs), which respond to an applied magnetic field, have excellent prospects for both diagnosis and therapy<sup>3</sup>. MRSNs can improve the field of theranostics and associated domains like magnetic separation, cellular labelling, immunoassays, MRI, magneto-sensors, and treatment-specific modalities like magnetic hyperthermia and magnetic-guided drug delivery. Suitable surface morphology, charge, or surface modification of MRSNs are useful for binding with biopolymers, nucleic acids, or optical dyes to facilitate multifunctional properties and targetability<sup>3,5–10</sup>.

Fatty liver is the earliest indication of many of the liver diseases, of which majority are believed to be the effect of factors like chronic infection with hepatitis B or C virus, heavy alcohol consumption, obesity, type 2 diabetes, smoking and after effects of aflatoxin-contaminated foods<sup>11–13</sup>. Fatty liver with hepatic inflammation may initiate with symptoms of fibrosis and progress to cirrhosis and finally lead to HCC in many cases, which is the leading sub type of primary liver cancer<sup>14–16</sup>. However, the disease is manageable and reversible by timely diagnosis of fibrosis and by proper therapeutic intervention at this stage<sup>17,18</sup>. Thus, the importance of early and accurate diagnosis and proper treatment is undoubtedly exemplified.

Though MRI is the best available in vivo diagnostic technique currently used for soft tissue imaging including cancerous transformations, it often requires external contrast agents for better visibility<sup>19–22</sup>. In the case of fatty liver, the accumulated fat has low response to conventional gadolinium-based contrast agents which is predominantly a positive contrast agent due to its prominent longitudinal relaxation ( $T_1$ ) property. So, contrast agents with transverse relaxation ( $T_2$ ) property that can provide  $T_2$  signal are preferred for liver imaging. Super paramagnetic metallic nanoparticles with proper surface coating are known for their competence for liver imaging<sup>23,24</sup>. Furthermore, they have additional thermal property in the presence of alternating current, to induce cell death, so that it can have the dual functions of diagnosis and therapy<sup>6,25,26</sup>.

In this study, we have developed superparamagnetic iron oxide nanoparticles (SPIONs) based multifunctional theranostic agent for liver associated diseases. Alginate stabilised SPIONs (ASPIONs) with average size of 40 nm, with excellent  $T_2$  relaxation and thermal property were developed for MR imaging and hyperthermia-based treatment. Additionally, a water-soluble dye with emission in the NIR range, Atto-700 coupled to SPIONs gave the optical imaging capability. Cyto compatibility, thermal property and imaging potential of SNs were evaluated in vitro and in vivo.

## Materials and methods

**Materials.**  $\text{FeCl}_3$  anhydrous,  $\text{FeCl}_2 \cdot 4\text{H}_2\text{O}$ , NaOH, 35% HCl (All from Merck, Germany/India) and Sodium Alginate Polysaccharide (Sigma Aldrich, India) were used for the preparation of ASPIONs. NIR emitting dye (Atto 700) was procured from Sigma Aldrich, India for optical imaging. Deionised Milli Q water of resistivity 18.2 M $\Omega$  was used throughout the work. All other chemicals and reagents used were of analytical grade.

For the cell culture study, Dulbecco's Modified Eagle's Medium (DMEM) (Himedia Laboratories Pvt. Ltd, Mumbai, India), sodium bicarbonate, Gentamicin (Himedia, Germany), Amphotericin B solution (Sigma-Aldrich, Germany), Fetal bovine serum (FBS), antibiotic-antimycotic mix (Himedia, India) and 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were used. HepG2 carcinoma cells were supplied from National Centre for Cell Science (NCCS, Pune, India). Carbon tetrachloride ( $\text{CCl}_4$ ) purchased from Spectrum Reagents & Chemicals Ltd, India and olive oil were used to develop fibrosis in rodents.

**Synthesis.** *Synthesis of SPIONs and ASPIONs.* Alkaline co-precipitation method was adopted for the preparation of SPIONs. Briefly,  $\text{FeCl}_3$  anhydrous and  $\text{FeCl}_2 \cdot 4\text{H}_2\text{O}$  were mixed in the 2:1 molar ratio in deionized water. The mixing continued until a homogenous solution was obtained. 1 M NaOH solution was added drop wise, and the mixture was maintained at 80 °C under inert atmosphere to obtain the SPIONs as the black precipitate. The same condition was maintained for another 2 h to complete the reaction. The SPIONs obtained were magnetically separated and washed by centrifugation with deionized water containing HCl.

The SPIONs were dispersed in 1.2% (w/v) sodium alginate solution and stirred overnight. The alginate coated SPIONs (ASPIONs) were washed by centrifugation to remove the alginate debris.

*Synthesis of ASPION-AT.* 1.2 mg ml<sup>-1</sup> concentration of ASPIONs (10 ml) was mixed with 20  $\mu\text{l}$  of 1.3  $\mu\text{g ml}^{-1}$  of Atto 700 dye and sonicated for about 6 h in the dark. After sonication, a color change from pale brown to pale green was considered as an indication for the formation of Atto modified ASPIONs (ASPION-AT). The suspension was centrifuged to eliminate the unreacted dye and used for further characterization.

*Physico chemical characterisation.* The particle size of the nanoparticle ASPIONs was analysed by Dynamic Light Scattering (DLS) technique and zeta potential by Zetasizer, Nano ZS with MPT-2 auto-titrator (Malvern Instruments Limited, UK) at 25 °C. The size and shape of the nanoparticles were examined by transmission electron microscopy at 100 kV (TEM, JEM-2010, JEOL, Tokyo, Japan). Samples were prepared by depositing a few droplets of dilute nanoparticles solution on to a formvar-coated copper grid.

The surface stabilisation and the structure of ASPIONs were studied using FTIR spectrometer (Thermo Nicolet 5700 FTIR spectrometer (USA)) using KBr pellet method. The structure and phase analysis of ASPIONs was analysed by means of X'Pert PRO X-ray diffraction (XRD) instrument using Cu K $\alpha$  radiation of 1.5406 Å at 40 kV and a 20 mA current. The crystal structure of the nanoparticles was assessed by evaluating the peak position and intensities at the diffraction angle range,  $2\theta$ —10° to 80°.

The thermal decomposition property of ASPION nanoparticles was studied using Thermo gravimetric analysis (TGA), SDT Q600 (simultaneous TGA-DTA, TA Instruments, USA) instrument. The lyophilised sample was analysed within a temperature range from 25 to 800 °C at a ramp rate of 10 °C min<sup>-1</sup> under nitrogen atmosphere.

The amount of alginate present in the ASPIONs was evaluated by the percentage decomposition at different temperatures and compared with that of bare alginate.

**Magnetic characterisation.** Lakeshore model 7410 vibrating sample magnetometer (VSM) was used to measure magnetic hysteresis of ASPIONs. A maximum magnetic field of 150 Oe was applied to obtain the measurement. The superparamagnetic nature and the saturation magnetization (Ms) of the ASPIONs was evaluated using the Magnetisation (M) versus magnetic field strength (H) plot.

Magnetic relaxivity measurements of ASPIONs were carried out using a 1.5 T whole body MRI scanner (MAGNETOM Avento Tim, Siemens, Munich, Germany) with a 12-channel radio frequency coil. Homogeneous aqueous phantoms of various Fe concentrations ranging from 0 to 0.45 mM were scanned under the MRI machine. By applying an inversion recovery MRI sequence, longitudinal relaxation time,  $T_1$  of the samples were measured. The repetition time (TR) and echo time (TE) were set at 4000 and 11 ms respectively and the MR signal was measured by changing the inversion time (TI) from 50 to 3000 ms. Transverse relaxation time,  $T_2$  was carried out using a modified  $T_2$  relaxometry spin echo sequence. At a fixed TR of 2000 ms and by varying TE from 15 to 120 ms (step size—15 ms) MR signal variation was measured. Using the resultant image pixel intensity maps corresponding to each concentration, longitudinal and transverse relaxation rates ( $r_1$  and  $r_2$ ) of ASPIONs were calculated via linear regression analysis by plotting relaxation rates against iron concentration.

The Magnetic hyperthermia efficiency of ASPIONs was examined using a laboratory induction system (Ambrell EASYHEAT, Rochester, USA) having a magnetic field frequency of 275 kHz. For heat generation, a solenoid coil with dimensions,  $4 \times 2.6$  cm (diameter and length) with a total number of 6 turns was set as the sample compartment. An alternating magnetic field (AMF) was applied to the sample. The variation in temperature of the nanoparticle in the aqueous suspension with respect to time was measured. At a fixed frequency of 275 kHz, current was altered from 200 to 400 A in steps of 50 A. By keeping a 1.5 ml non-magnetic vial with 1 ml of sample in distilled water suspension at the centre of the coil, induction heating treatment was carried out. Using a noncontact mode IR thermometer (Fluke 572, Germany), temperature profile was recorded at every 1 min. Specific loss power (SLP) of developed ASPIONs was evaluated using the following equation by means of the obtained temperature profile.

$$SLP = \frac{CV_s dT}{m dt}$$

where C is the volumetric specific heat capacity of the sample ( $C_{\text{water}} = 4185 \text{ J L}^{-1} \text{ K}^{-1} \text{ C}$ ),  $V_s$  is the sample volume, m is the mass of the magnetic material present in the sample volume and  $dT/dt$  is the initial linear rise in temperature versus time dependence<sup>27</sup>.

**Optical properties.** UV–Vis absorption spectroscopy (Shimadzu UV Spectrophotometer-UV-1800, Japan), fluorescence spectroscopy (Fluorolog-III; JobinYvon Inc., USA) and fluorescence imaging (Xenogen IVIS Spectrum) were performed to understand the optical property of ASPION–AT nanoparticles. Excitation wavelength of Atto dye, 680 nm was used to obtain the emission spectrum. The optical imaging capability of the Atto conjugated particles was analyzed using the optical imaging system (IVIS Spectrum).

**In vitro evaluations.** *In vitro cytotoxicity and reactive oxygen species (ROS) assessment.* The cytocompatibility of the particles was evaluated on hepatoma cells (HepG2) using MTT assay using standard protocols<sup>28</sup>.

A cell permeable probe 2',7'-dichlorodihydrofluorescein diacetate ( $H_2DCFDA$ ) was used to detect any intracellular ROS that is developed within the Hep G2 cells upon ASPION treatment. The assay was performed following instructions from the manufacturer (Invitrogen cat #C6827). The assay used  $10 \mu\text{M } H_2O_2$  as a positive control. ROS levels from untreated cells maintained under similar ambient conditions were used to normalize the ASPION treatment values and to minimize the background interference. The fluorescence intensity of the formed 2',7'-dichlorofluorescein as a result of carboxy-DCFDA hydrolysis was analysed in a 96-well spectrofluorimeter plate reader (Synergy H1 hybrid multi-mode microplate reader, Bio-Tek) at an excitation and emission wavelength of 492 and 527 nm respectively.

**In vitro magnetic hyperthermia.** For in vitro magnetic hyperthermia treatment, HepG2 cells seeded at a density of  $1 \times 10^4$  cells in 12 mm coverslips and incubated with  $2 \text{ mg ml}^{-1}$  of sterile ASPIONs and then subjected to alternating magnetic field of 33.8 mT and 275 kHz for 15 min. An infrared thermometer was used to monitor the temperature change in cell environment. Live/dead assay with dual staining using acridine orange and ethidium bromide was done to study the cell death induced by magnetic hyperthermia treatment. Cells without any treatment were used as control and cells incubated with ASPION alone without AMF treatment were also studied for comparison. Additionally, the cells after magnetic hyperthermia were studied using Environmental Scanning Electron Microscopy (ESEM-FEI QUANTA 200).

**In vivo imaging.** *Animal model development.* Prior approval from Institutional Animal Ethics Committee of Sree Chitra Tirunal Institute for Medical Sciences and Technology was obtained for the animal studies (No: B 2982011 IX, dated: 19-10-2011). All experiments were performed in accordance with the relevant guidelines and regulations. Animal study was carried out in compliance with the ARRIVE guidelines. Liver fibrosis in rat and mice model was developed as per the reported protocol using  $CCl_4$ -olive oil mixture<sup>29</sup>. Male Wistar rats ( $n=6$ ) weighing ~220 g were used for the in vivo MRI study.  $CCl_4$ -olive oil mixture (1:1 ratio) was injected intra-peritoneally twice a week for 6 weeks to induce liver fibrosis in rats. Male Swiss albino mice ( $n=6$ ) weigh-

ing ~ 35 g were used for optical imaging. Here, the liver fibrosis was developed by treating 1:7 ratio of  $\text{CCl}_4$ : olive oil mixture intra-peritoneally at the dosage of  $1 \mu\text{L g}^{-1}$  body weight, every 5 days, for 4 weeks. After the stipulated time, animals with elevated liver enzymes as evaluated by the liver function test were used for in vivo imaging.

**In vivo magnetic resonance imaging.** Whole body clinical MRI scanner (1.5 T) with a head coil was used for MR imaging of rat model of fibrosis. A multisection  $T_2$ -weighted turbo spin echo sequence (TE 125 ms; TR 5780 ms; flip angle 90; FOV 98 mm  $\times$  140 mm; slice thickness 3 mm) was used to carry out the MRI. Before administering the contrast agent, pre contrast imaging was carried out. ASPIONs was administered intravenously through tail vein at a dosage of  $2.17 \text{ mg ml}^{-1}$  (0.04 mM) Fe/kg body weight. After 15 min, post contrast images were also acquired. In order to assess signal intensity variation after contrast administration, signal intensity extraction and percentage evaluation was carried out on pre and post contrast images.

**In vivo optical imaging.** Liver fibrosis induced mice were administrated with ASPION-AT at a dosage of 0.04 mM of Fe/kg through tail vein and imaged using the Xenogen IVIS Spectrum imaging system. The excitation and emission filters corresponding to that of ATTO dye (675 and 720 nm respectively) was used. Fibrosis induced mice injected with saline was used as negative control. Ex vivo fluorescent images of the harvested organs were recorded after 2 h of injection (on sacrifice of the animals) to test for the organ specific targeting capability as well as particle distribution and clearance.

**Histopathology.** After 2 h of contrast (ASPION) injection, animals were euthanized by carbon dioxide asphyxiation method, and liver tissue was harvested from normal and fibrosis induced animals. Liver tissue was fixed with 10% neutral buffered formalin for 3 days and then embedded in paraffin and sectioned for further analysis. Pathological details of the liver tissue were evaluated using haematoxylin and eosin (H&E). Masson's Trichrome (MT) stain enabled the collagen fibres evaluation in liver tissues and the presence of iron was evaluated using Pearls' Prussian blue (PB) staining.

## Results and discussions


**Synthesis and characterization.** Co-precipitation method, an easy and convenient way of synthesis was used for the preparation of alginate stabilized SPIONs as a potential MR contrast and hyperthermia agent. Alginate, a naturally occurring biopolymer was preferred due to its attractive features like biocompatibility, biodegradability, antibacterial activity, hydrophilicity, and nontoxicity. Moreover, the presence of amenable functional groups for better reactivity for further functionalization was added advantage, which was utilized to conjugate optical probe to use it as a multimodal imaging nanoprobe. Till date, very few reports are available on alginate functionalized magnetic nanoparticles<sup>30–32</sup> and none extended the same to the development of multimodal nanoprobe for diagnosis and therapy, and has proven the concept in in vivo models.

TEM micrographs showed the average size of the ASPIONs as  $12 \pm 3 \text{ nm}$  without any aggregation (Fig. 1a) whereas the hydrodynamic diameter was  $38 \pm 4 \text{ nm}$  (Fig. 1b). Though several factor like the concentration of alkaline medium and the precipitation temperature can significantly influence the size of the materials formed, the hydrodynamic diameter of the material of current study matches with that of some of the previously reported alginate stabilized SPIONs<sup>31,32</sup>. XRD pattern of ASPIONs showed the inverse spinel structure of the magnetite phase (Fig. 1c) which corresponds to the JCPDS card No. 89-0691 and the previously reported work<sup>33</sup>. Infrared spectrum of sodium alginate (Fig. 1d) exhibited peaks around 3361, 1621, 1413 and  $1030 \text{ cm}^{-1}$  corresponding to the O–H, C–O, C–H and C–C vibrations. Shifts in the O–H, C–O and C–C peaks along with the undisturbed C–H vibration mode of alginate and the presence of Fe–O peak at  $582 \text{ cm}^{-1}$  confirm the formation of ASPIONs. TGA curve of Alginate (Fig. 1e) shows decomposition at  $85 \text{ }^\circ\text{C}$  followed by degradation at  $209 \text{ }^\circ\text{C}$  and  $268 \text{ }^\circ\text{C}$  with a 50% weight loss<sup>34</sup>. At the temperature around  $788 \text{ }^\circ\text{C}$ , a total weight loss of 77% was observed. The corresponding degradation of alginate in ASPIONs was around  $115 \text{ }^\circ\text{C}$ ,  $189 \text{ }^\circ\text{C}$ ,  $261 \text{ }^\circ\text{C}$  and  $794 \text{ }^\circ\text{C}$  with a total weight loss of 24% (Fig. 1f). The degradation temperature of ASPIONs got shifted to a lower temperature on comparison with that of the stabilizer, sodium alginate indicating an early decomposition of ASPIONs with temperature. Catalytic behavior of iron oxide nanoparticles is attributed to the observed shift in the decomposition temperature and the fast decomposition.

**Magnetic and thermal properties.** The magnetic nature and saturation magnetization of the ASPIONs was studied using vibrational sample magnetometry. Both SPIONs and ASPIONs showed the characteristic hysteresis pattern of superparamagnetic materials at room temperature, showing zero coercivity (Fig. 2a) and good magnetic saturation. The observed pattern of the hysteresis curve is an indication of the particle's single domain existence with only one orientation of magnetic moment. Here, the magnetization reduces from plateau region to zero on removal of the magnetic field. This further supports the magnetite phase of the developed material<sup>35</sup>. This is an essential property for the nanoprobe to work as a suitable  $T_2$  contrast agent. SPIONs showed high saturation magnetization of  $62.7 \text{ emu g}^{-1}$  whereas surface modification with alginate caused a slight decrease in saturation magnetization ( $53 \text{ emu g}^{-1}$ )<sup>36</sup>. It is also reported that superparamagnetic property helps in the uniform dispersion of the particles in solution without any aggregation<sup>37</sup>. Hence superparamagnetic property, which is highly influenced by the size of the particles, is important for smooth circulation of the material through the blood for its use as MRI contrast agent.

Based on the pixel intensity expressions of the MRI images of the colloidal phantom of the material, longitudinal and transverse relaxation rates  $r_1$  and  $r_2$  of ASPIONs were calculated. Transverse relaxivity rate was calculated from the slope of linear plot of  $1/T_2$  versus iron concentration. An  $r_2$  value of  $117.84 \text{ mM}^{-1} \text{ s}^{-1}$  was exhibited by ASPIONs (Fig. 2b). Longitudinal relaxivity rate value calculated by the linear fit has a value of  $3.86 \text{ mM}^{-1} \text{ s}^{-1}$  for





**Figure 1.** Size, shape and physico-chemical characterization of ASPION. (a) TEM image showing the shape and size of ASPIONS, (b) particle size distribution using dynamic light scattering graph, (c) XRD pattern of ASPION confirming the magnetite phase, (d) FTIR spectra of Alginate and ASPION and thermo gravimetric analysis of (e) alginate and (f) ASPION showing the thermal decomposition.


$r_1$ . The increase in  $T_2$  relaxivity compared to bare SPIONS<sup>36</sup> depends mainly on the effect of the delay in relaxation of the protons bound to the alginate coated SPION and the water protons<sup>38</sup>. Compared to other iron oxide based contrast agents of similar sizes,  $r_2$  of  $117.84 \text{ mM}^{-1} \text{ s}^{-1}$  and relaxivity ratio ( $r_2/r_1$ ) of 30.53 obtained for ASPIONS are high and hence is more suitable to use it as an efficient  $T_2$  contrast agent for MRI<sup>39–41</sup>.

ASPIONS were also evaluated for its heat generating capability for cancer therapy and the results are shown in Fig. 2c. A concentration of  $5 \text{ mg ml}^{-1}$  of ASPIONS raised the temperature to more than  $40\text{--}55 \text{ }^\circ\text{C}$  on the application of electric current varying from 200–400 A with a constant frequency of 275 kHz for 8 min, establishing it as an apt contender for hyperthermia. For the temperature based therapy, temperatures of the order of  $40\text{--}43 \text{ }^\circ\text{C}$  can favor efficient cancer cell death without destructing the surrounding normal cells<sup>42–45</sup>. The temperature rise could be optimized by adjusting the current. Here, the temperature was highest for the maximum current of 400 A. Evaluation of specific loss power (SLP) of a material can act as an indicator for the magnetic hyperthermia efficacy. SLP is defined as the amount of energy converted into heat per time and mass. It is reported that SLP critically depend on the diameter of  $\text{Fe}_3\text{O}_4$  nanoparticles, having a maximum at diameters  $\sim 16\text{--}17 \text{ nm}$ . SLP also depends slightly on the frequency of the applied AMF (in the range 100–500 kHz) which is directly proportional to the diameter of the nanoparticle in the range 13–20 nm. For nanoparticles having size above or below this range of diameter, SLP rapidly decreases to zero, and hyperthermia effect will not be achieved. Also, the SLP increases approximately in proportion to the increase in AMF frequency<sup>46</sup>.

Therapeutic efficacy of ASPIONS was calculated based on SLP and is given in Table 1. As the diameter of ASPIONS falls within the critical diameter and the frequency of the AMF chosen was also suitable for effective hyperthermia, ASPIONS enhanced the temperature and saturations on increasing the current of the AMF from 200 to 400 A.

**Optical properties.** Multimodal nanoprobe with both magnetic and optical properties was prepared by incorporating NIR emitting dye, Atto 700 with ASPION by physical interaction. Atto 700 is a zwitterionic dye with high fluorescence quantum yield, good water solubility and high photostability and is a strong electron acceptor. Simple electrostatic interaction of the hydroxyl groups of ASPIONS and  $\text{COO}^-$  group of Atto 700 dye resulted in the strong physical interaction between the two and formed a very stable complex, ASPION-AT.

The UV–Vis spectra of ASPION-AT showed an absorption maximum around 700 nm (Fig. 3a). The fluorescence excitation spectrum of ASPIONS-AT showed an excitation maximum at 680 nm and emission spectrum showed an emission maximum at 712 nm (Fig. 3b, c). The concentration dependent optical imaging efficiency of ASPION-AT using an optical imaging system is shown in Fig. 3d. Concentrations of the order of 0.03 mM dye provided good fluorescence intensity. The excitation–emission efficiency contour plot for the corresponding excitation–emission imaging is also shown in Fig. 3e. The contour plots showed two emission maxima at around 640 nm and 710 nm with the one at 710 nm being the most intense one as is seen by the intensity indicators in Fig. 3e. Atto 700 dye was chosen for its NIR emission property as this will avoid interference from the tissue




**Figure 2.** Magnetic property of NPs. (a) Magnetic hysteresis curves of SPION and ASPION showing characteristics of superparamagnetic nature. (b) Longitudinal and transverse relaxation images of ASPION in aqueous solution with varying concentrations (0–0.45 mM) (c) corresponding  $r_1$  and  $r_2$  relaxation rate of ASPIONs. (d) hyperthermia effect of ASPION under alternating magnetic field at current ranging from 200 to 400 A.

Sl no	Current through coil (A)	Magnetic field strength (mT)	SLP
			ASPION 5 mg ml <sup>-1</sup>
1	200	14.4	9.79
2	250	19.33	20.09
3	300	24.166	29.04
4	350	28.99	40.18
5	400	33.83	50.64

**Table 1.** Specific loss power values obtained for ASPIONs for varying current and magnetic field strength.

autofluorescence from the visible region during the in vivo application. The excitation emission maxima at 680 nm and 712 nm overruled the interference of autofluorescence from the animal body<sup>47–49</sup>. Fluorescence imaging of ASPION-AT showed remarkable fluorescence efficiency that makes it suitable for the in vivo application.


**Biocompatibility study.** Cytotoxicity of ASPIONs was assessed on hepatocellular carcinoma cells, HepG2 using MTT assay (Fig. 4a). Cell viability of 89, 94 and 106% were obtained respectively for ASPION concentrations 100, 50 and 25  $\mu\text{g ml}^{-1}$ . In MTT assay, total cell activity is measured on a normalized manner which is an



**Figure 3.** Optical properties of developed SNs (a) UV–visible absorption, (b) excitation and (c) emission spectra of Atto and ASPION-AT. (d) Fluorescence images of different concentrations of ASPION-AT (above) and the corresponding spectra excited at 675 nm with emission at 710 nm. (e) Excitation–Emission contour plot of ASPION-AT. The colour bar on the right gives an indication about the efficiency of the probe.

indirect representation of cell viability. It is quite usual to increase the total cell activity if the cell number is more with respect to previous count. This accounts for the observed cell viability of 106% in the lower concentration level of the material.

A consistent redox balance is always maintained to sustain a basal level of intracellular ROS at any point of time. Nanomaterial treatment in any cells, evoke the intracellular defence machinery to overcome any adverse reactions and mark increase in the ROS production. Any intracellular ROS that is developed within the HepG2 cells upon ASPION treatment was evaluated using  $H_2DCFDA$ . The results demonstrated only basal level of fluorescence signals arising from the ROS generated, from all the treatment concentrations even up to 40  $\mu M$  of ASPIONs post 24-h treatment (Fig. 4b). This result clearly indicates that there was no significant alteration in the intracellular redox balance, post ASPION treatment which is a good indicator for the application of ASPIONs for theranostic applications.




**Figure 4.** (a) Cytotoxicity evaluation of ASPIONs using different concentrations (25–100  $\mu g ml^{-1}$ ). (b) Quantification of reactive oxygen species generated from ASPIONs evaluated by DCFDA assay.

**In vitro hyperthermia.** Application of controlled temperature on cancerous cells can lead to apoptotic cell death<sup>25</sup>. Therefore apoptosis or programmed cell death via magnetic hyperthermia is a suitable methodology to annihilate cancer cells with nominal side effects<sup>50,51</sup>. In this study, we have evaluated hyperthermia potential of ASPIONs on hepatocellular carcinoma cells. For this, HepG2 cells were incubated with ASPIONs for 4 h and the cells were exposed to AMF for 15 min. Cells without any treatment served as control and cells treated with ASPIONs alone without exposing to AMF was used to evaluate material toxicity associated cell death. It is evident from the live/dead assay that control cells and cells incubated with ASPIONs alone without AMF exposure showed predominantly green signal which is the characteristic of live cells in live/dead assay (Fig. 5a, b). Whereas, most of the ASPION incubated cells exposed to AMF were positively stained for apoptotic cell death (Fig. 5c).

Further, the morphological changes of cancer cells by ASPION induced apoptosis by the magnetic hyperthermia was studied using ESEM. Control cells and cells incubated with ASPIONs alone without AMF exposure retained their normal morphology under ESEM (Fig. 5d, e). However, cells incubated with ASPIONs and exposed to AMF showed the characteristics of apoptosis like membrane blebbing, loss of structural integrity, cell shrinkage and rupture of cell membrane (Fig. 5f). This indicates that ASPIONs are effective candidates for magnetic hyperthermia-based cancer therapy.


**In vivo Magnetic Resonance Imaging.** Before the MRI imaging, the animals were tested for the enhancement in liver specific enzymes, AST and ALT to confirm the liver fibrosis model development. Selected animals were anesthetized and subjected to MRI using a 1.5 T MRI scanner. Pre and post contrast T<sub>2</sub> weighted coronal images and corresponding pseudo-colored images of the liver fibrosis induced animals are shown in Fig. 6a–d. ASPIONs enhance the image contrast of tissues through considerable shortening of T<sub>2</sub> relaxation times. The shortening of T<sub>2</sub> relaxation leads to a signal drop with a decrease in the pixel intensity at the sites where the SPIONs are accumulated. Average pixel intensity variation from the pre and post contrast liver also gave a remarkable difference of 54% between the two, indicating the clear visual difference between the images ( $p < 0.05$ ), whereas for normal rats, liver contrast variation was only 14.49% after administering ASPIONs. The achievement of significant signal intensity variation before and after the contrast injection is desired by using the contrast material, for a clear visibility of the pathological condition for an accurate and easy diagnosis. This is met with the material developed under the current study (Fig. 6e).

The hypointensity observed in the post-contrast T<sub>2</sub> weighted MR image is an indication of heavy uptake of ASPIONs by the liver cells. In the case ASPIONs, the carbohydrate polymer coating facilitates the enhanced permeability and retention based uptake of the material<sup>52,53</sup>. Within the hypointense liver, hyperintense streaks are visualized, which represents the Kupffer's cell devoid fibrotic regions of the liver. There is an excessive accumulation of extracellular matrix in fibrosed liver and hence a decrease in the Kupffer's cell density. As a result



**Figure 5.** In vitro hyperthermia using ASPIONs. (a–c) Live-dead cell assay and (d–f) ESEM images of HepG2 cells. (a & d) Controls, (b & e) with ASPION treatment without exposure to AMF and (c & f) with ASPION treatment and exposure to AMF.






**Figure 6.** In vivo MR imaging using developed SNs. (a & b) Pre and Post ASPION injected MRI images of liver fibrosis induced animal, respectively. (c & d) Corresponding pseudo colored images of pre and post contrast MRI for better visualization. (e) Signal intensity variation in percentage, extracted from liver area of pre and post contrast MRI. (f) In vivo fluorescence images of control and fibrosis induced mice acquired after administration of ASPION-AT intravenously. (g) Bio-distribution of ASPION-AT in different organs.

of the increase in the amount of collagen, the ratio of fibro-connective tissue versus liver cells increases at the fibrosed sites<sup>17,54</sup>.

**In vivo optical imaging using multimodal nanoprobe.** The imaging efficiency of the developed multimodal nanoprobe (ASPION-AT) was evaluated in the mice model of liver fibrosis. ASPION-AT administered rodents were imaged after 15 min of intravenous administration. Elevated fluorescence signal intensity was observed from the sites corresponding to the fibrosed liver (efficiency =  $7.92 \times 10^{-5} \pm 1.33 \times 10^{-5}$ ) compared to the control mice kept aside during imaging, for comparison (Fig. 6f). The NIR emitting ASPION-AT reduced the interference from autofluorescence of the mice and the images can be very well distinguished without any further post processing<sup>48</sup>. The organs of each mouse were excised after 1 h to check the bio distribution of the nanoprobe, which showed high fluorescence intensity in the liver (Fig. 6g). Absence of the signal from other organs confirm the targeted delivery or specific uptake of ASPION-AT by the liver while injected through intravenous route.

**Histopathological analysis.** H&E and MT stained images of normal liver revealed lobular architecture with central vein and radiating hepatic cords (Fig. 7a, b). However, the fibrotic liver revealed pronounced morphological alterations evidenced by disruption of the tissue architecture, moderate to severe necrosis of hepatocytes with infiltration of mononuclear cells and accumulation of fibers in peri-lobular and portal triad areas (Fig. 7d, e). The excessive accumulation of collagen fibers is very well distinguished in the MT stained sections of fibrosed liver (Fig. 7e), whereas this is absent in normal liver (Fig. 7b). Based on the H&E and MT staining procedures, the fibrous bridges dividing the liver into rounded islands of hepatic parenchyma resulting in the nodular formation surrounded by fibrous tissue has been observed in the liver. These histopathological observations reconfirm the development of fibrotic stage of liver in the rat model<sup>29,55</sup>. The iron uptake by the liver macrophages is insignificant in the case of PB stained normal liver (Fig. 7c) while the presence of iron in the fibrosed liver is confirmed, which was responsible for the hypointense MR image (Fig. 7f).



**Figure 7.** Histopathological evaluation of liver sections of control and fibrosis induced animals. Hematoxylin and Eosin, Masson's Trichrome and Perl's Prussian blue stained (a–c) control and (d–f) fibrosis induced liver sections.

## Conclusions

In this study, Alginate stabilized iron oxide nanoparticles with a hydrodynamic diameter of 40 nm was successfully developed and evaluated as a potential candidate for in vivo MR imaging of liver fibrosis. ASPIONs possess very good cytocompatibility validating its applicability to use in living systems. ASPIONs showed a very good proton relaxivity ratio ( $r_2/r_1$ ) of 30.53 at room temperature with an in vivo signal change of 54% in the  $T_2$  MRI after the intravenous administration. Application of varying magnetic field revealed the therapeutic efficiency of ASPIONs in hepatocellular carcinoma cells. Accounting these factors, ASPIONs can be considered as a potential candidate for the theranostics of liver associated diseases such as liver fibrosis. Further modification with NIR emitting Atto dye enabled the in vivo optical imaging with the enormous possibility of the probe to be used as a multifunctional theranostic tool. The developed SNs for in vivo imaging and hyperthermia of hepatocellular carcinoma and in vivo liver fibrosis is expected to play crucial role in the field of theranostics of liver diseases in the near future.

## Data availability

The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request.

Received: 2 October 2022; Accepted: 5 August 2023

Published online: 09 August 2023

## References

- Madamsetty, V. S., Mukherjee, A. & Mukherjee, S. Recent trends of the bio-inspired nanoparticles in cancer theranostics. *Front. Pharmacol.* **10**, 859. <https://doi.org/10.3389/fphar.2019.01264> (2019).
- Aflori, M. Smart nanomaterials for biomedical applications—a review. *Nanomater. (Basel, Switzerland)* **11**, 396. <https://doi.org/10.3390/nano11020396> (2021).
- Singh, R. *et al.* Smart nanomaterials for cancer diagnosis and treatment. *Nano Converg.* **9**, 21. <https://doi.org/10.1186/s40580-022-00313-x> (2022).
- Nair, R. V. *et al.* Luminescent gold nanorods to enhance the near-infrared emission of a photosensitizer for targeted cancer imaging and dual therapy: Experimental and theoretical approach. *Chem. A Eur. J.* **26**, 2826–2836. <https://doi.org/10.1002/chem.201904952> (2020).
- Tong, S., Quinto, C. A., Zhang, L., Mohindra, P. & Bao, G. Size-dependent heating of magnetic iron oxide nanoparticles. *ACS Nano* **11**, 6808–6816. <https://doi.org/10.1021/acsnano.7b01762> (2017).
- Shen, Z. *et al.* Multifunctional theranostic nanoparticles based on exceedingly small magnetic iron oxide nanoparticles for T1-weighted magnetic resonance imaging and chemotherapy. *ACS Nano* **11**, 10992–11004. <https://doi.org/10.1021/acsnano.7b04924> (2017).
- Yoshida, S. *et al.* MXD3 antisense oligonucleotide with superparamagnetic iron oxide nanoparticles: A new targeted approach for neuroblastoma. *Nanomed. Nanotechnol. Biol. Med.* **24**, 102127. <https://doi.org/10.1016/j.nano.2019.102127> (2020).
- Sun, Z. *et al.* Biodistribution of negatively charged iron oxide nanoparticles (IONPs) in mice and enhanced brain delivery using lysophosphatidic acid (LPA). *Nanomed. Nanotechnol. Biol. Med.* **12**, 1775–1784. <https://doi.org/10.1016/j.nano.2016.04.008> (2016).
- Cao, S.-W., Zhu, Y.-J., Ma, M.-Y., Li, L. & Zhang, L. Hierarchically nanostructured magnetic hollow spheres of Fe<sub>3</sub>O<sub>4</sub> and  $\gamma$ -Fe<sub>2</sub>O<sub>3</sub>: Preparation and potential application in drug delivery. *J. Phys. Chem. C* **112**, 1851–1856. <https://doi.org/10.1021/jp077468> (2008).



10. Xie, W. *et al.* Shape-, size- and structure-controlled synthesis and biocompatibility of iron oxide nanoparticles for magnetic therapeutics. *Theranostics* **8**, 3284–3307. <https://doi.org/10.7150/thno.25220> (2018).
11. Thun, M. J. *et al.* *Cancer Epidemiology and Prevention* (eds Thun, M. J. *et al.*) (Oxford Academic, 2017). <https://doi.org/10.1093/oso/9780190238667.001.0001>
12. Bosch, F. X., Ribes, J. & Borrás, J. Epidemiology of primary liver cancer. *Semin. Liver Dis.* **19**, 271–285. <https://doi.org/10.1055/s-2007-1007117> (1999).
13. Adami, H.-O. *et al.* Alcoholism and liver cirrhosis in the etiology of primary liver cancer. *Int. J. Cancer* **51**, 898–902. <https://doi.org/10.1002/ijc.2910510611> (1992).
14. Bruha, R., Dvorak, K. & Petřtyl, J. Alcoholic liver disease. *World J. Hepatol.* **4**, 81–90. <https://doi.org/10.4254/wjh.v4.i3.81> (2012).
15. Farrell, G. C. & Larter, C. Z. Nonalcoholic fatty liver disease: From steatosis to cirrhosis. *Hepatology* **43**, S99–S112. <https://doi.org/10.1002/hep.20973> (2006).
16. Tiniakos, D. G., Maurício, J. & Reeves, H. L. *Alcohol and Cancer*. (eds Vasiliou, V. *et al.*) 55–69 (Springer International Publishing).
17. Nazeer, S. S., Sandhyamani, S. & Jayasree, R. S. Optical diagnosis of the progression and reversal of CCl<sub>4</sub>-induced liver injury in rodent model using minimally invasive autofluorescence spectroscopy. *Analyst* **140**, 3773–3780. <https://doi.org/10.1039/c4an01507j> (2015).
18. Nazeer, S. S., Saraswathy, A., Shenoy, S. J. & Jayasree, R. S. Fluorescence spectroscopy as an efficient tool for staging the degree of liver fibrosis: An in vivo comparison with MRI. *Sci. Rep.* **8**, 10967. <https://doi.org/10.1038/s41598-018-29370-1> (2018).
19. Nidhin, M. *et al.* Flower shaped assembly of cobalt ferrite nanoparticles: Application as T-2 contrast agent in MRI. *RSC Adv.* **3**, 6906–6912. <https://doi.org/10.1039/C3ra23232h> (2013).
20. Nidhin, M. *et al.* Fluorescent nanonetworks: A novel bioalley for collagen scaffolds and tissue engineering. *Sci. Rep.* **4**, 1. <https://doi.org/10.1038/srep05968> (2014).
21. Nimi, N. *et al.* Multifunctional hybrid nanoconstruct of zerovalent iron and carbon dots for magnetic resonance angiography and optical imaging: An In vivo study. *Biomaterials* **171**, 46–56. <https://doi.org/10.1016/j.biomaterials.2018.04.012> (2018).
22. Ereath-Beeran, A. *et al.* An aqueous method for the controlled manganese (Mn<sup>2+</sup>) substitution in superparamagnetic iron oxide nanoparticles for contrast enhancement in MRI. *Phys. Chem. Chem. Phys.* **17**, 4609–4619. <https://doi.org/10.1039/c4cp05122j> (2015).
23. Nelson, N. R., Port, J. D. & Pandey, M. K. Use of superparamagnetic iron oxide nanoparticles (SPIONs) via multiple imaging modalities and modifications to reduce cytotoxicity: An educational review. *J. Nanotheranost.* **1**, 105–135 (2020).
24. Im, G. H. *et al.* Fe<sub>3</sub>O<sub>4</sub>/MnO hybrid nanocrystals as a dual contrast agent for both T1- and T2-weighted liver MRI. *Biomaterials* **34**, 2069–2076. <https://doi.org/10.1016/j.biomaterials.2012.11.054> (2013).
25. Laurent, S. & Mahmoudi, M. Superparamagnetic iron oxide nanoparticles: Promises for diagnosis and treatment of cancer. *Int. J. Mol. Epidemiol. Genet.* **2**, 367–390 (2011).
26. Beeran, A. E. *et al.* Multifunctional nano manganese ferrite ferrofluid for efficient theranostic application. *Colloids Surf. B* **136**, 1089–1097. <https://doi.org/10.1016/j.colsurfb.2015.11.010> (2015).
27. Fortin, J.-P. *et al.* Size-sorted anionic iron oxide nanomagnets as colloidal mediators for magnetic hyperthermia. *J. Am. Chem. Soc.* **129**, 2628–2635. <https://doi.org/10.1021/ja067457e> (2007).
28. Nimi, N. *et al.* Biosafety of citrate coated zerovalent iron nanoparticles for magnetic resonance angiography. *Data Brief* **20**, 1829–1835. <https://doi.org/10.1016/j.dib.2018.08.157> (2018).
29. Constantinou, C., Henderson, N. & Iredale, J. P. *Fibrosis Research: Methods and Protocols* (eds Varga, J. *et al.*) 237–250 (Humana Press, 2005).
30. Alpdemir, Ş *et al.* Magnetically responsive, sorafenib loaded alginate microspheres for hepatocellular carcinoma treatment. *IET Nanobiotechnol.* **14**, 617–622. <https://doi.org/10.1049/iet-nbt.2020.0139> (2020).
31. Ma, H.-L., Qi, X.-R., Maitani, Y. & Nagai, T. Preparation and characterization of superparamagnetic iron oxide nanoparticles stabilized by alginate. *Int. J. Pharm.* **333**, 177–186. <https://doi.org/10.1016/j.ijpharm.2006.10.006> (2007).
32. Peng, N. *et al.* High drug loading and pH-responsive targeted nanocarriers from alginate-modified SPIONs for anti-tumor chemotherapy. *Biomater. Sci.* **4**, 1802–1813. <https://doi.org/10.1039/c6bm00504g> (2016).
33. Nigam, S., Barick, K. C. & Bahadur, D. Development of citrate-stabilized Fe<sub>3</sub>O<sub>4</sub> nanoparticles: Conjugation and release of doxorubicin for therapeutic applications. *J. Magn. Magn. Mater.* **323**, 237–243. <https://doi.org/10.1016/j.jmmm.2010.09.009> (2011).
34. Shaiju, S. N., Ariya, S., Arun Kumar, G. & Ramapurath, S. J. Fluorescence spectroscopy to discriminate neoplastic human brain lesions: A study using the spectral intensity ratio and multivariate linear discriminant analysis. *Laser Phys.* **24**, 025602 (2014).
35. Gupta, A. K. & Wells, S. Surface-modified superparamagnetic nanoparticles for drug delivery: Preparation, characterization, and cytotoxicity studies. *IEEE Trans. Nanobiosci.* **3**, 66–73. <https://doi.org/10.1109/tnb.2003.820277> (2004).
36. Saraswathy, A. *et al.* Citrate coated iron oxide nanoparticles with enhanced relaxivity for in vivo magnetic resonance imaging of liver fibrosis. *Colloids Surf. B Biointerfaces* **117**, 216–224. <https://doi.org/10.1016/j.colsurfb.2014.02.034> (2014).
37. Manju, S., Sharma, C. P. & Sreenivasan, K. Targeted coadministration of sparingly soluble paclitaxel and curcumin into cancer cells by surface engineered magnetic nanoparticles. *J. Mater. Chem.* **21**, 15708–15717. <https://doi.org/10.1039/c1jm12528a> (2011).
38. Gunn, J., Paranjy, R. K. & Zhang, M. A simple and highly sensitive method for magnetic nanoparticle quantitation using 1H-NMR spectroscopy. *Biophys. J.* **97**, 2640–2647. <https://doi.org/10.1016/j.bpj.2009.08.013> (2009).
39. Lu, Z. *et al.* Size-tunable NaGdF<sub>4</sub> nanoparticles as T2 contrast agents for high-field magnetic resonance imaging. *RSC Adv.* **7**, 43125–43131. <https://doi.org/10.1039/c7ra08303c> (2017).
40. Najafian, N. *et al.* Effect of functional group and surface charge of PEG and dextran-coated USPIO as a contrast agent in MRI on relaxivity constant. *Appl. Magn. Reson.* **46**, 685–692. <https://doi.org/10.1007/s00723-015-0667-2> (2015).
41. Saraswathy, A. *et al.* Synthesis and characterization of dextran stabilized superparamagnetic iron oxide nanoparticles for in vivo MR imaging of liver fibrosis. *Carbohydr. Polym.* **101**, 760–768. <https://doi.org/10.1016/j.carbpol.2013.10.015> (2014).
42. Huang, H. S. & Hainfeld, J. F. Intravenous magnetic nanoparticle cancer hyperthermia. *Int. J. Nanomed.* **8**, 2521–2532. <https://doi.org/10.2147/IJN.S43770> (2013).
43. Silva, A. C. *et al.* Application of hyperthermia induced by superparamagnetic iron oxide nanoparticles in glioma treatment. *Int. J. Nanomed.* **6**, 591–603. <https://doi.org/10.2147/IJN.S14737> (2011).
44. Gao, F. *et al.* Pullulan acetate coated magnetite nanoparticles for hyper-thermia: Preparation, characterization and in vitro experiments. *Nano Res.* **3**, 23–31. <https://doi.org/10.1007/s12274-010-1004-6> (2010).
45. Saraswathy, A. *et al.* Asialoglycoprotein receptor targeted optical and magnetic resonance imaging and therapy of liver fibrosis using pullulan stabilized multi-functional iron oxide nanoprobe. *Sci. Rep.* **11**, 18324. <https://doi.org/10.1038/s41598-021-97808-0> (2021).
46. Caizer, C. Optimization study on specific loss power in superparamagnetic hyperthermia with magnetite nanoparticles for high efficiency in alternative cancer therapy. *Nanomaterials* **11**, 40 (2021).
47. del Rosal, B. & Benayas, A. Strategies to overcome autofluorescence in nanoprobe-driven in vivo fluorescence imaging. *Small Methods* **2**, 1800075. <https://doi.org/10.1002/smt.201800075> (2018).
48. Yang, S., Tan, X., Tang, L. & Yang, Q. Near-infrared-II bioimaging for in vivo quantitative analysis. *Front. Chem.* **9**, 89. <https://doi.org/10.3389/fchem.2021.763495> (2021).
49. Nair, L. V., Nazeer, S. S., Jayasree, R. S. & Ajayaghosh, A. Fluorescence imaging assisted photodynamic therapy using photosensitizer-linked gold quantum clusters. *ACS Nano* **9**, 5825–5832. <https://doi.org/10.1021/acsnano.5b00406> (2015).

50. Wang, Y.-X.J. Superparamagnetic iron oxide based MRI contrast agents: Current status of clinical application. *Quant. Imaging Med. Surg.* **1**, 35–40. <https://doi.org/10.3978/j.issn.2223-4292.2011.08.03> (2011).
51. Marcos-Campos, I. *et al.* Cell death induced by the application of alternating magnetic fields to nanoparticle-loaded dendritic cells. *Nanotechnology* **22**, 205101. <https://doi.org/10.1088/0957-4484/22/20/205101> (2011).
52. He, L., Shang, Z., Liu, H. & Yuan, Z.-X. Alginate-based platforms for cancer-targeted drug delivery. *Biomed. Res. Int.* **2020**, 1487259. <https://doi.org/10.1155/2020/1487259> (2020).
53. Jee, J.-P. *et al.* Cancer targeting strategies in nanomedicine: Design and application of chitosan nanoparticles. *Curr. Opin. Solid State Mater. Sci.* **16**, 333–342. <https://doi.org/10.1016/j.cossms.2013.01.002> (2012).
54. Van de Bovenkamp, M., Groothuis, G. M. M., Meijer, D. K. F. & Olinga, P. Liver fibrosis in vitro: Cell culture models and precision-cut liver slices. *Toxicol. In Vitro* **21**, 545–557. <https://doi.org/10.1016/j.tiv.2006.12.009> (2007).
55. Le Naour, F. *et al.* In situ chemical composition analysis of cirrhosis by combining synchrotron fourier transform infrared and synchrotron x-ray fluorescence microspectroscopies on the same tissue section. *Anal. Chem.* **84**, 10260–10266. <https://doi.org/10.1021/ac302072t> (2012).

## Acknowledgements

RSJ is thankful to Department of Biotechnology, Government of India for the support (BT/PR27222/NNT/28/1337/2017 and BT/INF/22/SP45155/2022). SSN acknowledges Department of Biotechnology, New Delhi, Government of India for the Ramalingaswami Re-entry fellowship.

## Author contributions

S.S.N., and A.S. contributed to the material synthesis, modification and physico chemical and biological studies of the nanoparticles. N.N. supported the synthesis of NIR dye conjugated nanoparticles. S.S.N. drafted the manuscript. H.S.K. and P.R.S. contributed to the biological characterization of the material. S.J.S. supported the animal studies. R.S.J. conceived the idea, acquired resources for the project, supervised the project and corrected the manuscript. All authors have read and edited the manuscript.

## Competing interests

The authors declare no competing interests.

## Additional information

**Correspondence** and requests for materials should be addressed to R.S.J.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023